The classical pathway (CP) of complement may contribute to the pathogenesis of antibody-mediated rejection (ABMR). Selective CP blockade may be a promising strategy to counteract rejection. The objective of this first-in-patient phase 1b trial was to evaluate the safety/tolerability and CP-blocking potential of 4 weekly doses (60 mg/ kg) of the anti-C1s antibody BIVV009 in complement-mediated disorders. Here we describe the results in a cohort of 10 stable kidney transplant recipients (median of 4.3 years posttransplantation) with late active ABMR and features of CP activation, such as capillary C4d or complement-fixing donor-specific antibodies (DSA). During 7 weeks follow-up, no severe adverse events were reported, and BIVV009 profoundly inhibited overall and DSA-triggered CP activation in serum. Five of 8 C4d-positive recipients turned C4d-negative in 5-week follow-up biopsies, while another 2 recipients showed a substantial decrease in C4d scores. There was, however, no change in microcirculation inflammation, gene expression patterns, DSA levels, or kidney function.
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inflammation and injury, and promotes adaptive immune responses.
1,2
The concept of alloantibody-triggered CP activation as a trigger of rejection is indirectly supported by 2 clinical observations: (1) capillary C4d in antibody-mediated rejection (ABMR), a marker of intragraft CP activation, is an independent predictor of adverse (ABO-compatible) allograft survival, 3, 4 and (2) C1q-fixing donor-specific antibodies (DSA) confer a greater risk of rejection and graft failure than nonC1q-fixing antibodies. 5 In addition, there is evidence suggesting that interference with complement could help prevent rejection in sensitized patients or ameliorate the course of established ABMR and thus positively affect graft survival. 6 Terminal complement blockade using the anti-C5 antibody eculizumab was reported to prevent acute ABMR in crossmatch-positive kidney transplant recipients, 7 and case reports have shown reversal of severe refractory acute rejection.
8,9
In a small randomized controlled pilot trial (15 patients), a 6-month course of eculizumab was suggested to stabilize the clinical course of chronic ABMR, even though in this context treatment did not affect morphologic and molecular rejection features. 
11,12
In a randomized controlled trial, treatment with C1-INH, in addition to "standard of care treatment" plasmapheresis and intravenous immunoglobulin, did not affect the primary endpoint (day 20 pathology or graft survival), although there was a trend toward improvement in renal function and less development of transplant glomerulopathy in 6-month follow-up biopsies.
12
These data offer some support for the concept of targeting C1
as a strategy to counteract ABMR. A promising strategy to shut down the CP may be the selective interference with the enzymatic C1 subcomponent C1s, which is essential for C4 cleavage and the subsequent formation of the CP C3 convertase. TNT003, a murine monoclonal anti-C1s antibody and its humanized variant BIVV009
(formerly TNT009), were shown to profoundly block chemotaxis of macrophages in experimental models of HLA antibody-triggered CP activation. [13] [14] [15] Recently, the same antibody was evaluated in healthy volunteers, 16 where it was found to be well tolerated and effectively block CP activity in the peripheral blood.
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The present first-in-patient single-arm phase 1b trial was primarily designed to investigate the safety/tolerability profile and the complement inhibitory activity of a short course of this novel antibody in a cohort of stable kidney transplant recipients on maintenance immunosuppression. The trial design took advantage of the fact that reversal of C4d staining can be an internal control for effect of the agent. Here we describe the CP-blocking potential of BIVV009 and, as preliminary efficacy endpoints, the morphologic and molecular evaluation of early follow-up biopsies from patients with late active ABMR and evidence of CP activation (in vivo C4d staining and/or detection of complement-fixing DSA in serum).
| MATERIALS AND METHODS

| Study design and objectives
This prospective phase 1 trial included a single cohort of 10 kidney transplant recipients diagnosed with late acute or chronic active ABMR. The study was part of a first-in-human phase 1 basket trial designed to assess the safety, tolerability, and potential efficacy of the humanized monoclonal anti-C1s antibody BIVV009 (formerly TNT009; Bioverativ Therapeutics, Inc., South San Francisco, CA) in healthy volunteers and patients with various diseases believed to be mediated by the CP (cold agglutinin disease, warm autoimmune hemolytic anemia, bullous pemphigoid, and ABMR). of the study is illustrated in Figure 1 . 
| Trial medication
For drug administration, patients were admitted to the study unit 
| Outcome measures
Study endpoints were evaluated until day 50 (end-of study visit).
The primary endpoint was the safety and tolerability of BIVV009, evaluating the incidence and severity of adverse events (AE) defined and classified according to the International Conference on Harmonization Guidelines for Good Clinical Practice. The protocol did not include an interim analysis. However, the trial was guided by an ongoing safety review process. Safety reviews were conducted in consultation with an independent data safety monitoring board, with the option of study interruption in case of unexpected clinical and laboratory findings raising safety concerns.
Secondary endpoints included the pharmacokinetics of BIVV009, the ability of BIVV009 to block the CP in serum and transplanted tissue (capillary C4d), the effect of BIVV009 on DSA mean fluorescence activity and C1q-fixing capability, and eGFR (Mayo equation) and spot urine protein/creatinine ratio. To assess the effect of BIVV009 on antibody-triggered inflammation/injury and gene expression patterns, patients underwent follow-up protocol biopsies at day 32.
| Antibody and complement detection
Antibody and complement assays were performed in samples taken at The ability of detected DSA to bind recombinant C1q was assessed on SAFB using the C1qScreen assay (One Lambda; MFI threshold:
DSA-triggered activation of key component C3 was assessed by measuring the deposition of the C3 complement split product C3d to SAFB (patient serum as complement source) following an earlier-described protocol. 15 In brief, patient sera were incubated for 30 minutes with SAFB at room temperature and then incubated with a biotin-conjugated monoclonal antibody against human C3d (4 μg/ mL; Quidel, San Diego, CA) for another 30 minutes. Subsequently, phycoerythrin-conjugated streptavidin (1 μg/mL; eBioscience, San Diego, CA) was added for 30 minutes. The threshold for C3d positivity was set to an MFI ≥100.
For assessment of overall CP complement activity, we applied 2 different assay principles. The Complement system Classical Pathway Wieslab ® assay to assess CP-triggered membrane attack complex activation was performed following manufacturer′s instructions (Euro-Diagnostica, Malmö, Sweden). In parallel, we evaluated the ability of sera from our patients dosed with BIVV009 to deposit complement in an earlier-described solid-phase assay that specifically detects third-party HLA antibody-triggered C3 activation. 17 In brief, patient sera were incubated with a mixture of HLA haplotype- 
| Biopsies
Renal allograft biopsies were performed using a 16-gauge needle.
We obtained 2 cores for light microscopy, electron microscopy, and gene expression analysis. For immunohistochemical C4d staining (performed on paraffin sections) we applied a polyclonal anti-C4d antibody (BI-RC4D, Biomedica, Vienna, Austria). C4d was scored 0 (negative), 1 (minimal), 2 (focal), and 3 (diffuse), respectively.
Minimal staining (C4d1) along peritubular capillaries (PTC) was considered as positive. For gene expression analysis, a 3-mm portion of a biopsy core was placed in RNAlater, stored at −20°C, and shipped at room temperature to the Alberta Transplant Applied Genomics Centre (ATAGC, University of Alberta, Edmonton, AB, Canada).
RNA extraction and gene expression analysis were performed using PrimeView GeneChip arrays (Affymetrix, Santa Clara, CA), as previously described in detail. 20, 21 Classifiers related to rejection (ABMR, TCMR, all rejection) or chronic kidney injury (atrophy/ fibrosis score) were generated on the basis of a reference set of 1208 biopsy specimens. 21 In addition, various pathogenesis-based transcripts (PBT) scores, which represent major biological events derived from experimental cell culture studies, mouse transplant studies, and human kidney transplants, and were shown to be involved in diverse annotated pathologic processes (eg cytotoxic T cell infiltration, γ-interferon effects, natural killer cell burden, and epithelial cell damage) were evaluated as earlier-described in detail. 22 Following the 2013 update of the Banff classification, 
| Statistical analysis
Continuous data are given as the median, interquartile range (IQR), and range. Discrete data are presented as counts and percentages.
For paired sample comparison, the Wilcoxon signed-rank test was used. A 2-sided P value <.05 was considered statistically significant. 
| RESULTS
This study, which was performed in the context of a first-in-human phase 1 basket trial, 16 included 10 kidney transplant recipients with late ABMR and signs of alloantibody-triggered CP activation (complementfixing DSA and/or C4d in PTC). ABMR was diagnosed after a median of 4.3 years posttransplantation, and the first study visit was carried out 38 (median; IQR: 28-45) days after the index biopsy. As shown in Figure 1 , study patients received BIVV009 at a 10 mg/kg test dose, followed by 4 weekly doses of 60 mg/kg, and underwent follow-up biopsies at day 32. Baseline characteristics are provided in Table 1 . Two patients were recipients of a live donor transplant, of which 1 was ABO-incompatible.
Three recipients had been subjected to immunoadsorption for desensitization 24 because of preformed DSA. At study inclusion, 9 patients were on tacrolimus-based immunosuppression. Median eGFR was 46 mL/ min per 1.73 m 2 and urinary protein/creatinine ratio was 399 mg/g. As detailed in Table 2 , immunodominant DSAs were commonly directed against HLA class II antigens (7 patients; individual DSA specificities:
see Table S1 ). Six patients showed significant C1q-, and 7 showed C3d-binding of their dominant DSA. Nine patients showed chronic/active, and 1 showed acute/active ABMR. Eight cases were C4d-positive. None of the patients had T cell-mediated rejection, and 1 index biopsy showed borderline changes. A sum score of glomerulitis and peritubular capillaritis (g+ptc score) was in median 4, and the median transplant glomerulopathy (cg) score was 2. The molecular ABMR score was in median 0.78 (Table 2 ).
| Impact of BIVV009 on CP activity in serum
BIVV009 treatment led to a profound and sustained blockade of serum CP activity detected in Wieslab ® assays (CP-triggered formation of the membrane attack complex) ( Figure 2 ). Four weeks after the last infusion, median CP activity was still <50%. 
| Impact of BIVV009 on C4d deposition in PTC
Follow-up biopsies performed 32 days after the first infusion indicated a significant decrease in median C4d scores, as shown for the 8 cases that were initially C4d-positive: 2 (IQR: 2-3) in index vs. 0 (0-1) in follow-up biopsies (P = .016) (Figure 3 ). Five recipients, of whom 3
showed a diffuse staining pattern (C4d3), turned C4d-negative, and 2 others showed only minimal staining (C4d1) in their follow-up biopsies. In a single case of an ABO-incompatible allograft focal staining (C4d2), however, no change in C4d staining was observed.
| Impact of BIVV009 on histomorphology and molecular biopsy results
As shown in Figure 3 [141-1222]; P = .88) from baseline to day 50 ( Figure 5 ). Repeated infusions were well tolerated. While all subjects had 1 or more mild or moderate AEs, severe adverse events (SAEs) did not occur (Table 3 ).
| Kidney function and safety outcomes
The most frequent events documented during the study period were headache (n = 3), peripheral edema (n = 3), and fatigue (n = 2). None of the AEs was considered to be related to treatment. While there was no case of bacterial or fungal infection, 1 recipient developed cytomegalovirus viremia (maximum of 3000 copies/mL) without clinical symptoms 6 weeks after study initiation, which was reversible under a course of oral valganciclovir.
| DISCUSSION
This first-in-patient pilot phase 1 trial was designed to assess the safety/tolerability profile of the anti-C1s monoclonal antibody BIVV009 in kidney transplant recipients. We investigated the ability of 4 weekly doses of the antibody to block the CP in patients with late ABMR, both in peripheral blood and in the rejecting allograft. BIVV009 profoundly inhibited CP activation and usually reduced or eliminated C4d staining, but short-course treatment had no effect on histologic or molecular features of ABMR activity in early follow-up biopsies.
BIVV009 led to a sustained blockade of the CP in serum, as indicated by a profound reduction in alloantibody-dependent C3 activation and CP-dependent terminal complex formation. In some patients, CP activity was inhibited over the whole study period. The relationship between CP blockade and BIVV009 serum concentrations was thereby consistent with previously experimental studies 13, 15 and a trial performed in healthy volunteers.
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The presence of C1q-fixing (vs non-C1q-fixing) DSA is a primary risk factor for graft loss in renal transplant recipients. 5 This observation, taken together with a diagnostic hallmark of ABMR, namely, capillary C4d deposition, 3, 4 suggests that DSA-mediated CP activation plays a major role in promoting the inflammatory response. Thus, a major finding was that a comparatively short course of CP blockade led to a marked reduction in C4d staining in early follow-up biopsies. 
26
The treatment duration was limited due to the early stage of clinical development. While this still allowed us to dissect the pharmacodynamics of BIVV009, in particular its CP inhibiting potential, it may not be suitable to draw valid conclusions regarding the effect of BIVV009 on the course of rejection. A remarkable finding was that, despite profound CP inhibition, the extent of microcirculation inflammation did not change over time. Moreover, there was no effect on molecular classifiers reflecting overall rejection or, more specifically, ABMR, and a diversity of analyzed PBTs remained unchanged. Of course, the uncontrolled design of the study and its small sample size may not allow for definitive conclusions, and the 4-week treatment course may have been too short to significantly modify rejection phenotypes. Nevertheless, the lack of effect on conventional and molecular measures of disease activity may raise some doubt about the role of CP in disease activity and pathogenesis of chronic active ABMR. Indeed, there is emerging evidence for a predominant role of Fc receptor-mediated cellular effector mechanisms, which may limit the efficacy of CP blockade in this specific context. 27, 28 At the same time, eculizumab was suggested to be effective in preventing acute ABMR, while long-term treatment in the context of chronic rejection was shown to be less effective. 7, 10, 29 In consideration of all these results, we believe that late chronic rejection should not be a primary target of treatment, and future trials evaluating the clinical efficiency of CP blockade should focus on the prevention and treatment of early ABMR.
Serial measurement of DSA revealed that there was no effect on DSA binding reflected by MFI or the ability of DSA to fix exogenous recombinant C1q, which may be mainly a function of IgG binding density in the SAFB assay. 30, 31 Considering the role of complement as a trigger of adaptive immunity, including B cell activation, 32 one may hypothesize that CP inhibition could modulate antibody production by CP inhibition, but the trial design and the short study period may have precluded detection of such effects on specific immunity.
Importantly, CP inhibition, even on the background of concomitant maintenance immunosuppression, was not associated with major toxicities, and during the study, no SAEs occurred. The observed beneficial safety profile is in accordance with data obtained in healthy volunteers, where BIVV009 was also well tolerated without any SAEs.
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This phase 1 trial has several limitations, in particular, the lack of a parallel-group design (to assess measures of disease activity, patients served as their own controls), limited treatment duration, and small sample size. Its design did not allow for detecting subtle effects on clinical outcomes, which would require much larger sample sizes and a randomized controlled design including a placebo-treated control arm.
At this early stage of drug development, however, safety was a primary issue and the study design did not intend for an extended treatment period. Nevertheless, we believe that the results of our study contribute significantly to a better understanding of the potential of a new approach of selective CP blockade.
In conclusion, we demonstrate that BIVV009 is able to block CP activity in both serum and renal tissue. Its high efficacy in terms of complement inhibition and a beneficial safety/tolerability profile, even when used with maintenance immunosuppression, provides a valuable foundation for future trials evaluating the potential of C1s blockade in the context of (early) transplant rejection or other disease states. Number of patients with 1 or more AE 10
Mild AE 6
Moderate AE 4
